Status:
COMPLETED
Dual Therapy Etravirine + Raltegravir by Once Daily in HIV-positive Patients (ETRAL QD)
Lead Sponsor:
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
Efficacy of etravirin + raltegravir dual therapy was showed in the ANRS 153 ETRAL protocol, in HIV-1 seropositive patients. The use of these two drugs avoids the use of nucleoside reverse transcriptas...
Detailed Description
The cART in one taken only a day (QD) improve the quality of life and promote the observance, especially in older patients with cognitive impairment beginning. The ETR+RAL (ETRAL) QD dual therapy shou...
Eligibility Criteria
Inclusion
- HIV-1 infected adult
- Treatment by ETRAL BID (etravirine 200 mg x 2/day + raltegravir 400 mg x 2/day) for at least 96 weeks
- plasma Viral Load \< 50 cp/ml the day of the switch for ETRAL QD
Exclusion
- Virologic failure under ETRAL BID (two consecutive plasma Viral Load \< 50 cp/ml)
- Applies contraindicated with etravirine
- Current pregnancy or pregnancy desire
Key Trial Info
Start Date :
January 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2019
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT03369743
Start Date
January 2 2018
End Date
December 30 2019
Last Update
May 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yasmine Dudoit
Paris, France, 75013